Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 14;124(4):744–753. doi: 10.1038/s41416-020-01180-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Percentage change from baseline to best response in target lesions is shown in patients with solid tumours (a), NC (b) and diffuse large B-cell lymphoma (DLBCL) (c). Only the largest decrease in the sum of the product or longest diameters for each eligible patient is shown in each figure. For patients with solid tumours, those with missing (n = 5) responses were excluded; one patient with prostate cancer who achieved SD as best response did not have a tumour diameter measurement and is not shown. Six patients with DLBCL without postbaseline tumour assessment were excluded. Among patients with solid tumours, a PR was reported in a patient with salivary gland cancer; SD was reported in patients with salivary gland cancer (n = 4), colorectal cancer (n = 5), oesophageal carcinoma (n = 1), non-small cell lung cancer (n = 1), prostate cancer (n = 7), breast cancer (n = 2), pancreatic cancer (n = 1), uterine cancer (n = 1), ovarian cancer (n = 2) and hepatic cancer (n = 1); PD was reported in patients with squamous cell carcinoma (n = 1), colorectal cancer (n = 4), non-small cell lung cancer (n = 1), poorly differentiated carcinoma of unknown origin (n = 1), pancreatic cancer (n = 1), breast cancer (n = 2), ovarian cancer (n = 1), gastrointestinal stromal tumour (n = 1), fallopian tube cancer (n = 1), endometrial cancer (n = 1) and adenocarcinoma pancreas (n = 1); and a patient with colorectal cancer had an unknown response.